SynthesisWorld journal of surgical oncology2021

The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials.

Qiangyun Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.